Abstracts tagged "Bone"

Abstract Number: 061 • 2020 Pediatric Rheumatology Symposium
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Farzana Nuruzzaman¹, Mingqian Huang ², Christian Hedrich ³, Hermann Girschick ⁴, Julie Cherian ¹, Karen Onel ⁵, T. Shawn Sato ⁶, Polly Ferguson ⁷ and Yongdong Zhao ⁸, ¹Stony Brook Children's Hospital, Stony Brook, ²Mount Sinai Hospital, New York, New York, ³University of Liverpool, Liverpool, United Kingdom, ⁴Wuerzburg, Germany, ⁵Hospital for Special Surgery, New York, ⁶University of Iowa, Iowa City, ⁷University of Iowa Carver College of Medicine, Iowa City, ⁸University of Washington, Seattle
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…
Abstract Number: 3 • 2019 ACR/ARP Annual Meeting
Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss
Ane Larrañaga-Vera¹, Francisco Conesa-Buendia ², Bruce Cronstein ³ and Aranzazu Mediero ², ¹NYU Langone Health, New York, NY, ²IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, ³NYU Langone, New York
Background/Purpose: Tenofovir is an anti-retroviral agent commonly used to treat human immunodeficiency virus (HIV)-infected patients as part of the drug regimen known as highly active…
Abstract Number: 1435 • 2019 ACR/ARP Annual Meeting
Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis
Angelo Fassio¹, GIovanni Adami ¹, Ombretta Viapiana ¹, Luca Idolazzi ¹, Giovanni Orsolini ¹, Alessandro Giollo ¹, Davide Gatti ² and Maurizio Rossini ¹, ¹University of Verona, Verona, Italy, ²Univerisity of Verona, Verona, Italy
Background/Purpose: Wnt signaling is an important regulator of bone remodeling and it is involved in the pathogenesis of focal and systemic bone loss in Rheumatoid…
Abstract Number: 1983 • 2019 ACR/ARP Annual Meeting
Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis
Jeroen Geurts¹, Cordula Netzer ², Stefan Schären ² and Thomas Hugle ³, ¹University Hospital Lausanne (CHUV), Lausanne, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: The absence of effective disease-modifying drugs remains an important unmet need in the treatment of osteoarthritis. In recent years, novel pharmacological treatments including targeting…
Abstract Number: 2196 • 2019 ACR/ARP Annual Meeting
Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)
Michael Bowes¹, Katherine Kacena ², Oras Alabas ³, Alan Brett ¹, Bright Dube ⁴, Neil Bodick ⁵ and Philip G Conaghan ⁶, ¹Imorphics, Manchester, England, United Kingdom, ²BioBridges, Wellesley Hills, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴University of Leeds, LEEDS, England, United Kingdom, ⁵Flexion Therapeutics, Burlington, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Osteoarthritis (OA) is a slowly progressing disease which may be asymptomatic for many years. Therapy development has been hampered by poor understanding of both…
Abstract Number: 2206 • 2018 ACR/ARHP Annual Meeting
Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis
Scott Brunet^1,2,3, Sarah Manske^1,2,3, Klaus Engelke^4,5, Steven K. Boyd^1,2,3 and Cheryl Barnabe^2,6, ¹Biomedical Engineering, University of Calgary, Calgary, AB, Canada, ²McCaig Institute for Bone and Joint Health, Calgary, AB, Canada, ³Department of Radiology, University of Calgary, Calgary, AB, Canada, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Medicine, Erlangen University Hospital, Erlangen, Germany, ⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Functional decline and reduced quality of life for patients with rheumatoid arthritis (RA) results from chronic changes to joints in patients, including bone erosions…
Abstract Number: 2207 • 2018 ACR/ARHP Annual Meeting
Detecting Hand Joint Ankylosis in Radiographic Images Using Deep Learning: A Step in Development of Automatic Radiographic Scoring System for Bone Destruction
Keisuke Izumi^1,2, Masahiro Hashimoto³, Kanata Suzuki⁴, Toshio Endoh⁴, Kentaro Doi⁵, Yuki Iwai⁵, Masahiro Jinzaki³, Shigeru Ko⁶ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ³Department of Radiology, Keio University School of Medicine, Tokyo, Japan, ⁴Machine Learning Technology Project, Artificial Intelligence Laboratory, FUJITSU LABORATORIES LTD., Kawasaki, Japan, ⁵SOLUTIONS DEVELOPMENT DEPT.I, MEDICAL SOLUTIONS DIV.V, Healthcare Solutions Unit. II, FUJITSU LTD., Tokyo, Japan, ⁶Department of Systems Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Artificial intelligence (AI) techniques including deep learning have been rapidly evolving and shown good performance in many fields over recent years. However, there are…
Abstract Number: 40 • 2018 ACR/ARHP Annual Meeting
IFN Regulatory Factor 3 but Not IFN Regulatory Factor 7 Contributes to Bone Erosion in Collagen Induced Arthritis
Susan Sweeney¹, David L. Boyle², Yuya Fujita³, Anthony Bui⁴, Gary S. Firestein² and Maripat Corr⁵, ¹Lilly Research Laboratories, Eli Lily, San Diego, CA, ²Medicine, University of California San Diego, La Jolla, CA, ³Medicine, University of California San Diego, La jolla, CA, ⁴Medicine, University of California San Diego, San Diego, CA, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Type I interferons and their mRNA signatures have become prominent in biomarkers of autoimmune and autoinflammatory disease activity. Two master regulators of type I…
Abstract Number: 2210 • 2018 ACR/ARHP Annual Meeting
Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study
Ikuko Tanaka¹, Takashi Kato², Motokazu Kai³, Kunikazu Ogawa³, Hiroaki Mizuno¹, Mari Ushikubo⁴, Keisuke Izumi⁵, Hisaji Oshima⁶ and Shigenori Tamaki¹, ¹Nagoya Rheumatology Clinic, Nagoya, Japan, ²Department of Radiology, National Center for Geratrics and Gerontology, Obu, Japan, ³Mie Rheumatology Clinic, Suzuka, Japan, ⁴National Tokyo Medical Center, Tokyo, Japan, ⁵Department of connective Tissue Disease, National Tokyo Medical Center, Tokyo, Japan, ⁶Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) induces systemic osteoporosis as well as osteoporotic change in the bones having arthritis by RA. Recently immune complex and anti-citrullinated peptide…
Abstract Number: 41 • 2018 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Improves Bone Strength in Mouse Model for Rheumatoid Arthritis
Ryuusuke Kaneko, Fumihito Hosoi, Satoru Iguchi, Hiroaki Hayashi, Yohei Yoshiga, Yoshinori Nakachi, Daichi Akasaka, Kenji Tanaka, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Nelson B. Watts¹, Robin K. Dore², Sanford Baim³, Gary Hattersley⁴, Greg Williams⁵, Yamei Wang⁴, Tamara D. Rozental⁶ and Meryl S. LeBoff⁷, ¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²Univ of California, Los Angeles, CA, ³Rush Medical College, Chicago, IL, ⁴Radius Health, Inc., Waltham, MA, ⁵Clinical Development, Radius Health, Inc., Waltham, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…
Abstract Number: 53 • 2018 ACR/ARHP Annual Meeting
Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Shunsuke Tsujimoto, Kyohei Horie, Toshiya Mashiko, Johji Nomura and Tsunefumi Kobayashi, Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the hypertrophy of synovial fibroblasts,…
Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Chad Deal¹, Bruce Mitlak², Yamei Wang², Lorraine A Fitzpatrick² and Paul D Miller³, ¹Cleveland Clinic, Shaker Heights, OH, ²Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…
Abstract Number: 57 • 2018 ACR/ARHP Annual Meeting
Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model
Dale Wright, Ben Zweifel, Steve Settle and Rick Fitch, Pharmacology, Mallinckrodt Pharmaceuticals, Hazelwood, MO
Background/Purpose: Repository corticotropin injection (RCI: H.P. Acthar® gel) contains a purified porcine pituitary ACTH-analogue, and is an FDA-approved treatment for short-term adjunctive therapy of acute…
Abstract Number: 2308 • 2018 ACR/ARHP Annual Meeting
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
Jean Yves Reginster¹, Florence Bianic², Rosanne Campbell², Monique Martin², Setareh A. Williams³ and Lorraine A Fitzpatrick³, ¹Université de Liège, Liège, Belgium, ²inVentiv Health, London, United Kingdom, ³Radius Health, Inc., Waltham, MA
Background/Purpose: To assess the relative efficacy of abaloparatide compared with other osteoporosis treatment options (alendronate, denosumab, ibandronate, raloxifene, risedronate, romosozumab, strontium ranelate, teriparatide, zoledronic acid).…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].